Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    Expert review of anticancer therapy · 2022
    GVGaurav Varma
    PMID: 35726803DOIFirst author1 citations
  2. 2
    Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    GVGaurav Varma
    PMID: 38568191DOIFirst author

Publications

22 publications

Clinical research

6 studies

Active

6 studies
  • PI
    Expanded Access Program (EAP) for Obecabtagene Autoleucel (Obe-cel) Out-of-specification (OOS) in Adult Patients With Acute Lymphoblastic Leukemia
    Autolus INC · OPEN TO ACCRUAL (as of 2026)
    Lymphoblastic Leukemia, Acute, Adult; B Cell ALL
    NCT06799221
  • PI
    A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
    PHASE2 · SWOG Cancer Research Network · OPEN TO ACCRUAL (as of 2024)
    Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
    NCT05633615
  • PI
    Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
    Kite Pharma, Inc. · OPEN TO ACCRUAL (as of 2024)
    Large B-cell Lymphoma; Follicular Lymphoma
    NCT05776160
  • PI
    Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
    Kite Pharma, Inc. · OPEN TO ACCRUAL (as of 2024)
    Mantle Cell Lymphoma; Acute Lymphoblastic Leukemia
    NCT05776134
  • PI
    Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release
    Juno Therapeutics, Inc. · OPEN TO ACCRUAL (as of 2021)
    Lymphoma, Large B-Cell, Diffuse
    NCT04400591
  • PI
    Managed Access Programs for CTL019, Tisagenlecleucel
    Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2019)
    Lymphoma; Leukemia; Off-label Indications
    NCT03601442

External relationships

Other

Kite Pharma, Inc. · Sophos IRB INC